{"id":1977,"date":"2009-05-31T00:00:00","date_gmt":"2009-05-31T07:00:00","guid":{"rendered":"https:\/\/vermont.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/"},"modified":"2018-01-26T14:34:04","modified_gmt":"2018-01-26T22:34:04","slug":"genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/zh\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/","title":{"rendered":"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro"},"content":{"rendered":"

La Jolla, CA\u2014A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic.\n<\/p>\n

\n“It’s been ten years since human stem cells were first cultured in a Petri dish,” says the study’s leader Juan-Carlos Izpis\u00faa Belmonte<\/a>, Ph.D., a professor in the Gene Expression Laboratory and director of the Center of Regenerative Medicine in Barcelona (CMRB), Spain. “The hope in the field has always been that we’ll be able to correct a disease genetically and then make iPS cells that differentiate into the type of tissue where the disease is manifested and bring it to clinic.”\n <\/p>\n

<\/p>\n

Genetically-corrected fibroblasts from Fanconi anemia patients (shown in green at the top) are reprogrammed to generate induced pluripotent stem cells, which, in turn, can be differentiated into disease-free hematopoietic progenitors, capable of producing blood cells in vitro (bottom: Erythroid colonies.)\n <\/p>\n

\nImage: Courtesy of Dr. Juan-Carlos Belmonte, Salk Institute for Biological Studies.<\/p>\n<\/div>\n

\nAlthough several studies have demonstrated the efficacy of the approach in mice, its feasibility in humans had not been established. The Salk study offers the first proof that this technology can work in human cells.\n <\/p>\n

\nBelmonte’s team, working with Salk colleague Inder Verma, Ph.D., a professor in the Laboratory of Genetics, and colleagues at the CMRB, and the CIEMAT in Madrid, Spain, decided to focus on Fanconi anemia (FA), a genetic disorder responsible for a series of hematological abnormalities that impair the body’s ability to fight infection, deliver oxygen, and clot blood. Caused by mutations in one of 13 Fanconi anemia (FA) genes, the disease often leads to bone marrow failure, leukemia, and other cancers. Even after receiving bone marrow transplants to correct the hematological problems, patients remain at high risk of developing cancer and other serious health conditions.\n <\/p>\n

\nAfter taking hair or skin cells from patients with Fanconi anemia, the investigators corrected the defective gene in the patients’ cells using gene therapy techniques pioneered in Verma’s laboratory. They then successfully reprogrammed the repaired cells into induced pluripotent stem (iPS) cells using a combination of transcription factors, OCT4, SOX2, KLF4 and cMYC. The resulting FA-iPS cells were indistinguishable from human embryonic stem cells and iPS cells generated from healthy donors.\n <\/p>\n

\nSince bone marrow failure as a result of the progressive decline in the numbers of functional hematopoietic stem cells is the most prominent feature of Fanconi anemia, the researchers then tested whether patient-specific iPS cells could be used as a source for transplantable hematopoietic stem cells. They found that FA-iPS cells readily differentiated into hematopoietic progenitor cells primed to differentiate into healthy blood cells.\n <\/p>\n

\n“We haven’t cured a human being, but we have cured a cell,” Belmonte explains. “In theory we could transplant it into a human and cure the disease.”\n <\/p>\n

\nAlthough hurdles still loom before that theory can become practice-in particular, preventing the reprogrammed cells from inducing tumors-in coming months Belmonte and Verma will be exploring ways to overcome that and other obstacles. In April 2009, they received a $6.6 million from the California Institute Regenerative Medicine (CIRM) to pursue research aimed at translating basic science into clinical cures.\n <\/p>\n

\n“If we can demonstrate that a combined iPS-gene therapy approach works in humans, then there is no limit to what we can do,” says Verma.\n <\/p>\n

\nFor information on the commercialization of this technology, the Salk Office of Technology Development at (858) 453-4100, Ext. 1278.\n <\/p>\n

\nResearchers who also contributed to the work include first author \u00c1ngel Raya, as well as Ignasi Rodr\u00edguez-Piz\u00e0, Rita Vassena, Mar\u00eda Jos\u00e9 Barrero, Antonella Consiglio, Eduard Sleep, Federico Gonz\u00e1lez, Gustavo Tiscornia, Elena Garreta, Trond Aasen, and Anna Veiga of the Center for Regenerative Medicine in Barcelona, Spain; Guillermo Guenechea, Susana Navarro, Paula R\u00edo, and Juan Bueren of the Hematopoiesis and Gene Therapy Division, Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas in Madrid, Spain; and Maria Castell\u00e0 and Jordi Surrall\u00e9s of the Department of Genetics and Microbiology, Universitat Autonoma de Barcelona.\n<\/p>\n

\nAbout the Salk Institute for Biological Studies:<\/strong>
\nThe Salk Institute for Biological Studies is one of the world’s preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused on both discovery and mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer’s, diabetes, and cardiovascular disorders by studying neuroscience, genetics, cell and plant biology, and related disciplines.\n<\/p>\n

\nFaculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.<\/p>","protected":false},"featured_media":0,"template":"","faculty":[115,85],"disease-research":[],"class_list":["post-1977","disclosure","type-disclosure","status-publish","hentry","faculty-inder-verma","faculty-juan-carlos-izpisua-belmonte"],"acf":[],"yoast_head":"\nGenetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/zh\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"La Jolla, CA\u2014A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/zh\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2018-01-26T22:34:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/\",\"name\":\"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/caption_20090531.jpg\",\"datePublished\":\"2009-05-31T07:00:00+00:00\",\"dateModified\":\"2018-01-26T22:34:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/caption_20090531.jpg\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2015\\\/03\\\/caption_20090531.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/zh\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/","og_locale":"zh_CN","og_type":"article","og_title":"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies","og_description":"La Jolla, CA\u2014A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic.","og_url":"https:\/\/www.salk.edu\/zh\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2018-01-26T22:34:04+00:00","og_image":[{"width":628,"height":329,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/","url":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/","name":"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2015\/03\/caption_20090531.jpg","datePublished":"2009-05-31T07:00:00+00:00","dateModified":"2018-01-26T22:34:04+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2015\/03\/caption_20090531.jpg","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2015\/03\/caption_20090531.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/genetic-re-disposition-combined-stem-cell-gene-therapy-approach-cures-human-genetic-disease-in-vitro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"Genetic Re-disposition: Combined stem cell-gene therapy approach cures human genetic disease in vitro"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"\u7d22\u5c14\u514b\u751f\u7269\u7814\u7a76\u6240","description":"The Power of Science","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"\u7d22\u5c14\u514b\u751f\u7269\u7814\u7a76\u6240","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"","journal_title":"","paper_author_list":"","paper_title":"","subhead":"","home_photo":"belmonte-verma_360.jpg","listing_photo":"","gallery":false,"legacy_boilerplate":[],"hide_boilerplate":[],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/1977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":1,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/1977\/revisions"}],"predecessor-version":[{"id":16219,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/1977\/revisions\/16219"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/media?parent=1977"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/faculty?post=1977"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disease-research?post=1977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}